You are here

  • Home
  • Archive
  • Volume 68, Issue 8
  • Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond

Article info

Article menu
Download PDFPDF
Letter
Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond

Authors

  1. W M Kooloos, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, NL 2300 RC Leiden, The Netherlands; w.m.kooloos{at}lumc.nl
View Full Text

Citation

Kooloos WM, Wessels JAM, van der Kooij SM, et al
Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A–677C alleles on probability to respond
Annals of the Rheumatic Diseases 2009;68:1371.

Publication history

  • Accepted October 29, 2008
  • First published July 15, 2009.
Online issue publication 
March 09, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

2009 BMJ Publishing Group and European League Against Rheumatism